Monilinia mali
Monilinia mali is a fungal pathogen that primarily affects apple trees. It is responsible for a disease known as apple brown rot, which can cause significant damage to apple crops.
Taxonomy[edit]
Monilinia mali is a member of the Ascomycota phylum, which is the largest phylum of fungi, comprising about 75% of all fungal species. It belongs to the Sclerotiniaceae family, which includes many other important plant pathogens.
Description[edit]
Monilinia mali is characterized by its ability to produce conidia, which are asexual spores that are spread by wind or water. These conidia are typically oval in shape and have a smooth surface. The fungus also produces sclerotia, which are hardened masses of mycelium that can survive in the soil for extended periods.
Disease Cycle[edit]
The disease cycle of Monilinia mali begins when the fungus overwinters in infected apple fruit or in the soil as sclerotia. In the spring, the sclerotia germinate and produce conidia, which are spread to healthy apple trees by wind or rain. Once on the apple tree, the conidia germinate and infect the apple fruit, causing brown rot. The infected fruit eventually falls to the ground, where the fungus can overwinter and start the disease cycle again the following year.
Management[edit]
Management of Monilinia mali involves a combination of cultural practices and chemical control. Cultural practices include pruning infected branches and removing infected fruit from the tree and ground. Chemical control typically involves the application of fungicides during the growing season.
Economic Impact[edit]
Monilinia mali can cause significant economic losses in apple orchards. The fungus can infect a large percentage of the apple crop, rendering the fruit unmarketable. In addition, the cost of managing the disease can be substantial.
See Also[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian

